
|Articles|April 16, 2007
Tigan suppositories removed from market
Trimethobenzamide-containing suppositories are the next product in line to hit the FDA's chopping block as part of the agency's ongoing effort to ensure that all marketed drugs have been officially approved. The rectally administered treatment of nausea and vomiting has been available under the brand names Tigan, Tebamide, Trimazide, Trimethobenz, and T-Gen.
Advertisement
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Pharmacists Can Play Central Role in Patients’ Infusion Services | ASHP Midyear 2025
2
Women Seek Holistic Interventions for Improving Health Outcomes
3
FDA Expands Approval of Flibanserin for Postmenopausal Women’s Sexual Health
4
What TrumpRx Means for Independent Pharmacies and Their Patients
5




























































































































